hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status

Gemcitabine is still one of the standard chemotherapy regimens for pancreatic ductal adenocarcinoma (PDAC). Gemcitabine uptake into tumor cells is mainly through the human equilibrative nucleoside transport 1 (hENT1). It was therefore proposed as a potential predictive biomarker of gemcitabine effic...

詳細記述

保存先:
書誌詳細
出版年:Cancers (Basel)
主要な著者: Raffenne, Jerome, Nicolle, Remy, Puleo, Francesco, Le Corre, Delphine, Boyez, Camille, Marechal, Raphael, Emile, Jean François, Demetter, Peter, Bardier, Armelle, Laurent-Puig, Pierre, de Mestier, Louis, Paradis, Valerie, Couvelard, Anne, VanLathem, Jean Luc, MacKey, John R., Bachet, Jean-Baptiste, Svrcek, Magali, Cros, Jerome
フォーマット: Artigo
言語:Inglês
出版事項: MDPI 2019
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6896053/
https://ncbi.nlm.nih.gov/pubmed/31752123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11111808
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料